The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Role of the SPA17-AXL Pathway in Melanoma Progression and the Antitumor Potential of SPA17-Targeted Vaccination

  • By

  • Lan Zhang

  • Mengshu You

  • Bin Yan

  • Jian Zhang

  • Yi Yao

  • Qingyan Zhang

  • Zuozhong Xie

  • Shixiang Wang

  • Qian Gao

  • September 9, 2026

Share

  • 1

    SPA17 is overexpressed in melanoma and correlates with poor prognosis, increased metastatic burden, and resistance to immunotherapy.

  • 2

    Knockdown of SPA17 in melanoma cells inhibits migration and reduces tumor growth in vivo without affecting cell proliferation.

  • 3

    SPA17 depletion enhances CD8+ T-cell infiltration and cytotoxic activity against melanoma cells, indicating its role in immune evasion.

  • 4

    AXL is a critical downstream effector of SPA17, with its overexpression rescuing migration defects and restoring lymphocyte-mediated killing.

  • 5

    Therapeutic vaccination targeting SPA17 significantly restrains melanoma progression and increases tumor-infiltrating CD8+ T cells.

Original Source(s)

The SPA17-AXL axis drives melanoma aggressiveness and SPA17-targeting vaccination exhibits antitumor efficacy

  • by Lan Zhang, Mengshu You, Bin Yan, Jian Zhang, Yi Yao, Qingyan Zhang, Zuozhong Xie, Shixiang Wang, Qian Gao

  • September 9, 2026

Related Content

The Circadian Skin: Chronobiology as a New Frontier in Dermatological Therapy

Editorial: Tumor microenvironment and personalized therapy of gastrointestinal cancer Ⅱ

Physical exercise in brain tumor patients: a systematic review